JP2005520498A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005520498A5 JP2005520498A5 JP2003552803A JP2003552803A JP2005520498A5 JP 2005520498 A5 JP2005520498 A5 JP 2005520498A5 JP 2003552803 A JP2003552803 A JP 2003552803A JP 2003552803 A JP2003552803 A JP 2003552803A JP 2005520498 A5 JP2005520498 A5 JP 2005520498A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- seq
- polynucleotide
- sequence
- isolated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001184 polypeptide Polymers 0.000 claims 37
- 102000004196 processed proteins & peptides Human genes 0.000 claims 37
- 108090000765 processed proteins & peptides Proteins 0.000 claims 37
- 108091033319 polynucleotide Proteins 0.000 claims 27
- 239000002157 polynucleotide Substances 0.000 claims 27
- 102000040430 polynucleotide Human genes 0.000 claims 27
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 9
- 150000001875 compounds Chemical class 0.000 claims 9
- 210000004027 cell Anatomy 0.000 claims 7
- 230000000694 effects Effects 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 239000002773 nucleotide Substances 0.000 claims 4
- 125000003729 nucleotide group Chemical group 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 3
- 108020001507 fusion proteins Proteins 0.000 claims 3
- 102000037865 fusion proteins Human genes 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 239000012528 membrane Substances 0.000 claims 3
- 230000000295 complement effect Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 239000000523 sample Substances 0.000 claims 2
- 238000012216 screening Methods 0.000 claims 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- 238000012286 ELISA Assay Methods 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 210000000170 cell membrane Anatomy 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 239000001963 growth medium Substances 0.000 claims 1
- 238000009396 hybridization Methods 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 238000002372 labelling Methods 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 238000010561 standard procedure Methods 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34165201P | 2001-12-17 | 2001-12-17 | |
| PCT/EP2002/014339 WO2003051923A2 (en) | 2001-12-17 | 2002-12-16 | Novel g-protein coupled receptors and dna sequences thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005520498A JP2005520498A (ja) | 2005-07-14 |
| JP2005520498A5 true JP2005520498A5 (enExample) | 2006-01-26 |
Family
ID=23338470
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003552803A Pending JP2005520498A (ja) | 2001-12-17 | 2002-12-16 | 新規ｇタンパク質共役受容体およびそのｄｎａ配列 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20050107589A1 (enExample) |
| EP (1) | EP1458755A2 (enExample) |
| JP (1) | JP2005520498A (enExample) |
| AU (1) | AU2002361429A1 (enExample) |
| WO (1) | WO2003051923A2 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0511844D0 (en) * | 2005-06-10 | 2005-07-20 | Novartis Ag | Organic compounds |
| MX2009000645A (es) | 2006-07-17 | 2009-03-06 | Novartis Ag | Derivados de sulfonilaminocarbonilo de amidas de acido biliar para utilizarse en la forma de inmunomoduladores. |
| EA200901375A1 (ru) * | 2007-04-13 | 2010-04-30 | Новартис Аг | Производные пиридазина, пиридина и пирана в качестве агонистов рецептора gpbar1 |
| US8822663B2 (en) | 2010-08-06 | 2014-09-02 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| CA2821992A1 (en) | 2010-10-01 | 2012-04-05 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| DE12722942T1 (de) | 2011-03-31 | 2021-09-30 | Modernatx, Inc. | Freisetzung und formulierung von manipulierten nukleinsäuren |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| HRP20220250T1 (hr) | 2011-10-03 | 2022-04-29 | Modernatx, Inc. | Modificirani nukleozidi, nukleotidi i nukleinske kiseline, te njihove uporabe |
| SI2791160T1 (sl) | 2011-12-16 | 2022-07-29 | Modernatx, Inc. | Sestave modificirane MRNA |
| US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
| AU2013243952A1 (en) | 2012-04-02 | 2014-10-30 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| SMT202200337T1 (it) | 2012-11-26 | 2022-09-14 | Modernatx Inc | Rna modificato al livello del terminale |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| US10323076B2 (en) | 2013-10-03 | 2019-06-18 | Modernatx, Inc. | Polynucleotides encoding low density lipoprotein receptor |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002008258A2 (en) * | 2000-07-21 | 2002-01-31 | Millennium Pharmaceuticals, Inc. | 65494, a human g-protein-coupled receptor family member and uses thereof |
| EP1273659A4 (en) * | 2000-04-12 | 2004-04-21 | Takeda Chemical Industries Ltd | G-PROTEIN COUPLED RECEPTOR PROTEIN AND ITS DNA |
| US7198914B2 (en) * | 2000-11-17 | 2007-04-03 | Banyu Pharmaceutical Co., Ltd. | Guanosine triphosphate (GTP)-binding protein-coupled receptor protein, BG37 |
| US7354726B2 (en) * | 2001-04-12 | 2008-04-08 | Takeda Pharmaceutical Company Limited | Screening method |
| DE60228559D1 (de) * | 2001-04-25 | 2008-10-09 | Astellas Pharma Inc | Guanosintriphosphat-bindungsprotein-gekoppelter rezeptor place 6002312 und sein gen sowie dessen produktion und verwendung |
| WO2003004678A2 (en) * | 2001-07-03 | 2003-01-16 | Tularik Inc. | Novel receptors |
-
2002
- 2002-12-16 WO PCT/EP2002/014339 patent/WO2003051923A2/en not_active Ceased
- 2002-12-16 US US10/497,762 patent/US20050107589A1/en not_active Abandoned
- 2002-12-16 EP EP02796647A patent/EP1458755A2/en not_active Withdrawn
- 2002-12-16 AU AU2002361429A patent/AU2002361429A1/en not_active Abandoned
- 2002-12-16 JP JP2003552803A patent/JP2005520498A/ja active Pending
-
2006
- 2006-09-29 US US11/537,424 patent/US20070275391A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005520498A5 (enExample) | ||
| JP6076581B2 (ja) | Ｔｉａｂｓを検出するための組成物及び方法 | |
| US20110053787A1 (en) | Compositions and Methods of Detecting Post-Stop Peptides | |
| JP2006500948A5 (enExample) | ||
| CA2735129A1 (en) | Syngap1 dysfunctions and uses thereof in diagnostic and therapeutic applications for mental retardation | |
| JP2012501452A5 (enExample) | ||
| KR20090052861A (ko) | 전사 부정확, 검출 및 이의 용도 | |
| Ramachandran et al. | Tracking humoral responses using self assembling protein microarrays | |
| JP2004500013A5 (enExample) | ||
| WO2002022884A2 (en) | Microarrayed organization of transcription factor target genes | |
| CN119069003A (zh) | 一种先天性心脏病合并智力发育落后的预测系统及电子设备 | |
| JP2005502344A5 (enExample) | ||
| WO2002014550A2 (en) | Transcription factor target gene discovery | |
| JP2009539370A5 (enExample) | ||
| WO2003076897A2 (en) | Multiplexed analysis of cellular responses using endogenous reporter genes | |
| JPH07508407A (ja) | 分子生物学的診断のための方法およびシステム | |
| CN111748640A (zh) | 肠道菌群在肌少症中的应用 | |
| CA2318486A1 (en) | Novel nucleic acid molecules correlated with the rhesus weak d phenotype | |
| CA2456037A1 (en) | Paget disease of bone | |
| KR102343240B1 (ko) | 대장암 환자에서 세툭시맙에 대한 내성 예측용 바이오마커 조성물 | |
| JP2003532369A5 (enExample) | ||
| CN118326058B (zh) | iNK细胞中iPSC的标志物及其应用 | |
| EP4453236B1 (en) | Methods and systems for analyzing target engagement data from biological assays | |
| Marziliano et al. | Transcriptomic and proteomic analysis in the cardiovascular setting: unravelling the disease? | |
| JP2005525826A5 (enExample) |